Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative
| Autor: | Eduardo Lasalvia-Prisco, Eduardo Lasalvia-Galante, Wilson Golomar, Joshemaria Larrañaga, S. Cucchi, Jesús Vázquez, Emilio Garcia-Giralt |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Cancer Research Immunogen medicine.medical_treatment Population Breast Neoplasms T-Lymphocytes Regulatory Breast cancer Antigen medicine Humans Prospective Studies education Aged education.field_of_study business.industry Cancer Immunotherapy Middle Aged medicine.disease Metastatic breast cancer Oncology Immunology Cancer research Disease Progression Female Cancer vaccine business |
| Zdroj: | Breast cancer research and treatment. 100(2) |
| ISSN: | 0167-6806 |
| Popis: | Introduction Advanced breast cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal. We tested a recently described medical procedure using a thermostable autohemoderivative purported to inhibit tumor growth possibly through an immunological mechanism of action. Patients and methods Metastatic breast cancer patients, chemotherapy-resistant, high CEA and CA 15-3 plasma levels of tumor markers, in progression, were 2-group randomized. Group 1 received the test procedure and Group 2 adequate measures to be comparable control. From 121 included patients, 108 could be evaluated. During 8-month follow-up period, tumor growth, number of cases attaining clinical non-progressive status and mortality were monthly assessed. Immunologic effect was assessed by delayed type hypersensitivity test and lymphocyte proliferation assay. Responding-tumors histopathologies were studied. The proteome of the autologous immunogen was characterized by 2-D electrophoresis. Results and discussion In a significant number of cases, the test procedure promoted inhibition of tumor growth, non-progressive disease status, and lower cumulative mortality. These clinical results were associated with polyvalent immunization against several tested antigens: the hemoderivative used for treatment, the blood tumor markers and the derivative obtained from a regulatory lymphocyte population (CD4+CD25+). Interference with this regulatory activity could explain the selective autoimmunity suggested by the histopathology findings in responding tumors. The thermostability could be an essential property of the immunogen hemoderivative. Conclusion The thermostable autohemoderivative tested is antigenically polyvalent and promoted a polytargeted immune response associated to a tumor anti-progressive effect, consequently, acting as an autohemoderivative cancer vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink